The AlphaLISA Human Mutant Ataxin-2 Detection Kit is designed for the quantitative determination of mutant Ataxin-2 in cell and tissue lysates using a homogeneous (no wash steps, no separation steps) assay.
Feature | Specification |
---|---|
Application | Protein Quantification |
Sample Volume | 10 µL |
The AlphaLISA Human Mutant Ataxin-2 Detection Kit is designed for the quantitative determination of mutant Ataxin-2 in cell and tissue lysates using a homogeneous (no wash steps, no separation steps) assay.
The ATXN2 gene encodes the RNA-binding protein called Ataxin 2. When bearing lengthy polyglutamine tracts, Ataxin 2 causes neurodegeneration, which speeds up the onset of ALS illness. According to recent research in neurodegenerative diseases, TDP-43 regulates the expression of Ataxin 2, and in cellular and animal models, Ataxin 2 changes the toxicity of TDP-43. New research indicates that reduced Ataxin 2 levels prevent TDP-43 aggregation, suggesting that future therapy efforts should investigate both proteins in tandem.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Application |
Protein Quantification
|
---|---|
Automation Compatible |
Yes
|
Brand |
AlphaLISA
|
Detection Modality |
Alpha
|
Product Group |
Kit
|
Sample Volume |
10 µL
|
Shipping Conditions |
Shipped in Blue Ice
|
Target |
Ataxin-2
|
Target Class |
Biomarkers
|
Technology |
Alpha
|
Therapeutic Area |
Neuroscience
|
Unit Size |
100 assay points
|
Are you looking for resources, click on the resource type to explore further.
Dr. Muñoz-Sanjuan, Vice President of Translational Biology at CHDI Foundation, a private non-profit research organization focused...
We are here to answer your questions.